An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease

Journal of Experimental Medicine

Volumn 187, Issue 4, 1998, Pages 537-546

  Segal, Benjamin M ^a   Dwyer, Bonnie K ^a,b   Shevach, Ethan M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MYELIN BASIC PROTEIN; NEUTRALIZING ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; HELPER CELL; IMMUNOREGULATION; LYMPH NODE CELL; LYMPHOCYTE DIFFERENTIATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; SPLEEN; TH1 CELLS;

EID: 0032536447     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.187.4.537     Document Type: Article

References (83)

1. Mosmann, T.R., and R.L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
2. Sher, A., and R.L. Coffman. 1992. Regulation of autoimmunity to parasites and T cell-derived cytokines. Annu. Rev. Immunol. 10:385-409.
3. Liblau, R.S., S.M. Singer, and H.O. McDevitt. 1995. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today. 16:34-38.
4. Zamvil, S.S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:579-621.
5. Bergman, B., and K. Haskins. 1994. Islet-specific T-cell clones from the NOD mouse respond to β-granule antigen. Diabetes. 43:197-203.
6. Romball, C.G., and W.O. Weigle. 1987. Transfer of experimental autoimmune thyroiditis with T cell clones. J. Immunol. 138:1092-1098.
7. Germann, T., J. Szeliga, H. Hess, S. Storkel, F.J. Podlaski, M.K. Gately, E. Schmitt, and E. Rude. 1995. Administration of interleukin-12 in combination with type ii collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA. 92:4823-4827.
8. Xu, H., L.V. Rizzo, P.B. Silver, and R.R. Caspi. 1997. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell. Immunol. 178:69-78.
9. de Carli, M., M.M. D'Elios, S. Marrioti, G. Marcocci, A. Pinchera, M. Ricci, S. Romagnani, and G. del Prete. 1993. Cytolytic T cells with Th1-like cytokine profiles predominate in retroorbital lymphocytic infiltrates of Graves' opthalmopathy. J. Clin. Endocrinol. Metab. 77:1120-1124.
10. Navikas, V., and H. Link. 1996. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Research. 45: 322-333.
11. Simon, A.K., E. Seipelt, and J. Seiper. 1994. Divergent T cell cytokine patterns in inflammatory arthritis. Proc. Natl. Acad. Sci. USA. 91:8562-8566.
12. Whitcup, S.M., and R.B. Nussenblatt. 1997. Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch. Ophthamol. 115:520-525.
13. Trembleau, S., T. Germann, M.K. Gately, and L. Adorini. 1995. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today. 16:383-386.
14. Locksley, R.M. 1994. Th2 cells: help for helminths. J. Exp. Med. 179:1405-1407.
15. Goldman, M., P. Druet, and E. Gleichmann. 1991. Th2 cells in systemic autoimmunity. Immunol. Today. 12:223-227.
16. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179:589-600.
17. + T cells. Immunity. 1:553-562.
18. Katz, J.D., C. Benoist, and D. Mathis. 1995. T helper cell subsets in insulin-dependent diabetes. Science. 268:1185-1188.
19. Saoudi, A., J. Kuhn, K. Huygen, Y. de Kozak, T. Velu, M. Goldman, P. Druet, and B. Bellon. 1993. Th2 activated cells prevent experimental autoimmune uveoretinitis, a Th1-dependent autoimmune disease. Eur. J. Immunol. 23:3096-3103.
20. Cua, D.J., D.R. Hinton, and S.A. Stohlman. 1995. Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J. Immunol. 155:4052-4059.
21. Ando, D.G. J. Clayton, D. Kong, J.L. Urban, and E. Sercarz. 1989. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphocyte subtype. Cell. Immunol. 124:132-143.
22. Baron, J.L., J.A. Madri, N.H. Ruddle, G. Hashim, and C.A. Janeway, Jr. 1993. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57-68.
23. Powell, M.B., D. Mitchell, J. Lederman, J. Buckmeier, S.S. Zamvil, M. Graham, N.H. Ruddle, and L. Steinman. 1990. Lymphotoxin and tumor necrosis-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogencity. Intern. Immunol. 2:539-544.
24. Khoruts, A., S.D. Miller, and M.K. Jenkins. 1995. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J. Immunol. 155:5011-5017.
25. Brocke, S., K. Gibjels, M. Allegrata, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D.J. Mitchell et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:343-346.
26. Nicholson, L.B., J.M. Greer, R.A. Sobel, M.A. Lees, and V.K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents experimental autoimmune encephalomyelitis. Immunity. 3:397-405.
27. Chen, Y., V.K. Kuchroo, J. Inobe, D.A. Hafler, and H.L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237-1240.
28. Van der Veen, R.C., and S.A. Stohlman. 1993. Encephalitogenic Th1 T cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J. Neuroimmunol. 48:213-220.
29. Kennedy, M.K., D.S. Torrance, K.S. Picha, and K.M. Mohler. 1992. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental allergic encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:2496-2505.
30. Issazadeh, S., A. Ljungdahl, B. Hojeberg, M. Mustafa, and T. Olsson. 1995. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J. Neuroimmunol. 61:205-212.
31. Issazadeh, S., J.C. Lorentzen, M.I. Mustafa, B. Holeberg, A. Mussener, and T. Olsson. 1996. Cytokines in relapsing experimental allergic encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming factor-beta. J. Neuroimmunol. 69:103-115.
32. Ruddle, N.H., C.M. Bergman, K.M. McGrath, E.G., Lingenheld, M.L. Grunnet, S.J. Padula, and R.B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193-1200.
33. Selmaj, K., C.S. Raine, and A.H. Cross. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694-700.
34. Klinkert, W.E.F., K. Kojima, W. Lesslauer, W. Rinner, H. Lassman, and H. Wekerle. 1997. TNF-α receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview. J. Neuroimmunol. 72:163-168.
35. Selmaj, K., W. Paplerz, A. Glabinski, and T. Kohno. 1995. Prevention of chronic relapsing autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:135-141.
36. Genain, C.P., T. Roberts, R.L. Davis, A. Nguyen, M. Uccelli, D. Faulds, Y. Li, J. Hedgpeth, and S.L. Hauser. 1995. Prevention of autoimmune damage in non-human primates by a cAMP specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA. 92:3602-3605.
37. Sommers, N., P.A. Loschmann, G.H. Northoff, M. Weller, A. Steinbrecher, J.P. Steinbach, R. Lichtenfels, R. Meyermann, A. Rietmuller, A. Fontana et al. 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:244-248.
38. Crisi, G.M., L. Santambrogio, G.M. Hochwald, S.R. Smith, J.A. Carlino, and G.J. Thorbecke. 1995. Staphylococcal enterotoxin B and tumor-necrosis factor-α-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-β and interleukin-10. Eur. J. Immunol. 25:3035-3040.
39. Racke, M.K., A. Bonomo, D.E. Scott, B. Canella, A. Levine, C.S. Raine, E.M. Shevach, and M. Rocken. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961-1966.
40. Rott, O., B. Fleischer, and E. Cash. 1994. Interleukin-10 prevents experimental autoimmune encephalomyelitis in rats. Eur. J. Immunol. 24:1434-1440.
41. Shaw, M.K., J.B. Lorens, A. Dhawan, R. DalCanto, H.Y. Tse, A.B. Tran, C. Bonpane, S.L. Eswaran, S. Brocke, N. Sarvetnick et al. 1997. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1711-1714.
42. Mathisen, P.M., M. Yu, J.M. Johnson, J.A. Drazba, and V.K. Tuohy. 1997. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186:159-164.
43. Billiau, A., H. Heremans, F. Vandekerckhove, R. Dijkmans, H. Sobis, E. Meulepas, and H. Carton. 1988. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ J. Immunol. 140:1506-1510.
44. Duong, T., J. St. Louis, J.J. Gilbert, F.D. Finkelman, B. Singh, and G.H. Strejan. 1992. Effect of anti-interferon-γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J. Neuroimmunol. 36:105-115.
45. Duong, T., F. Finkelman, B. Singh, and G. Strejan. 1994. Effect of ann-IFN-γ monoclonal antibody treatment on the development of experimental allergic encephalomyelitis in resistant mouse strains. J. Neuroimmunol. 53:101-107.
46. Heremans, H., C. Dillen, M. Groenen, E. Martens, and A. Billiau. 1996. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-γ. Eur. J. Immunol. 26: 2393-2398.
47. Lublin, F.D., R.L. Knobler, B. Kalman, M. Goldhaber, J. Marini, M. Perrault, C. D'Imperio, J. Joseph, S.S. Alkan, and R. Korngold. 1993. Monoclonal anti-γ interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity. 16:267-274.
48. Voorthuis, J., B. Uitdehaag, C. De Groot, P. Goede, P. van der Meide, and C. Dijkstra. 1990. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-γ in Lewis rats. Clin. Exp. Immunol. 81: 183-188.
49. Ferber, I.A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C.G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156:5-7.
50. Krakowski, M., and T. Owens. 1996. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26:1641-1646.
51. Willenborg, D.O., S. Fordham, C.C.A. Bernard, W.B. Cowden, and I.A. Ramshaw. 1996. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157:3223-3227.
52. Frei, K., H.-P. Eugster, M. Bopst, C.S. Constantinescu, E. Lavi, and A. Fontana. 1997. Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185: 2177-2182.
53. Liblau, R., L. Steinman, and S. Brocke. 1997. Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Intern. Immunol. 9:799-803.
54. Lafaille, J.J., F. Van de Keere, A.L. Hsu, J.L. Baron, W. Haas, C.S. Raine, and S. Tonegawa. 1997. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from disease. J. Exp. Med. 186:307-312.
55. Pakala, S.V., M.O. Kurrer, and J.D. Katz. 1997. T helper 2 (Th2) cells induce pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J. Exp. Med. 186: 299-306.
56. Magram, J., S.E. Connaughton, R.R. Warrier, D.M. Carvajal, C.-Y. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D.A. Faherty, and M.K. Gately. 1996. IL-12 deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity. 4:471-181.
57. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
58. Trinchieri, G. 1997. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-γ). Curr. Opin. Immunol. 9:17-23.
59. O'Garra, A., R. Chang, N. Go, R. Hastings, G. Haughton, and M. Howard. 1992. Ly-1 B (B-1) cells are the main source of B cell-derived interleukm 10. Eur. J. Immunol. 22:711-717.
60. Fearon, D.T., and R.M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science. 272:50-54.
61. Medzhitov, R., and C.A. Janeway, Jr. 1997. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9:4-9.
62. Segal, B.M., and E.M. Shevach. 1996. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184: 771-775.
63. Segal, B.M., D.M. Klinman, and E.M. Shevach. 1997. Microbial products induce autoimmune disease by an IL-12 dependent pathway. J. Immunol. 158:5087-5090.
64. Leonard, J.P., K.E. Waldburger, and S.J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381-386.
65. Trembleau, S., G. Penna, E. Bosi, A. Mortara, M.K. Gately, and L. Adorini. 1995. Interleukin 12 induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J. Exp. Med. 181:817-821.
66. Mosmann, T.R., J.H. Schumacher, D.F. Fiorentino, J. Leverah, K.W. Moore, and M.W. Bond. 1990. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbant assay. J. Immunol. 145:2938-2945.
67. + T cells. Annu. Rev. Immunol. 12:635-673.
68. Schoenhaut, D.S., A.O. Chua, A.G. Wolitzky, P.M. Quinn, C.M. Dwyer, W. McComas, P.C. Familletti, M.K. Gately, and U. Gubler. 1992. Cloning and expression of murine IL-12. J. Immunol. 148:3433-3440.
69. Scharton-Kersten, T.M., T.A. Wynn, E.Y. Denkers, S. Bala, E. Grunvald, S. Hieny, R.T. Gazzinelli, and A. Sher. 1996. In the absence of endogenous IFN-γ. mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157:4045-4054.
70. Cooper, A.M., J. Magram, J. Ferrante, and I.M. Orme. 1997. Interleukin 12 (IL-12) 15 crucial to the development of protective immunity in mice infected with mycobacterium tuberculosis. J. Exp. Med. 186:39-45.
71. Tripp, C.S., M.K. Gately, J. Hakimi, P. Ling, and E.R. Unanuae. 1994. Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma. J. Immunol. 152:1883-1887.
72. Morris, S.C., K.B. Madden, J.J. Adamovicz, W.C. Gause, B.R. Hubbard, M.K. Gately, and F.D. Finkelman. 1994. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol. 152:1047-1056.
73. Wang, Z., S. Zheng, D. Corry, D.K. Dalton, R.A. Seder, S.L. Reiner, and R.M. Locksley. 1994. Interferon-γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc. Natl. Acad. Sci. USA. 91:12932-12936.
74. Taylor, A.P., and H.W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice. J. Exp. Med. 185:1231-1239.
75. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M.K. Gately, J.A. Louis, and G. Abler. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1553-1559.
76. Bendelac, A., and D.T. Fearon. 1997. Innate pathways that control acquired immunity. Curr. Opin. Immunol. 9:1-3.
77. + T cells in a Th2 response and in Immunoglobulin E production. Science. 270:1845-1847.
78. + T lymphocytes. Science. 268:863-865.
79. + Th1-like responses. J. Clin. Invest. 98: 1010-1020.
80. + T cells and accompanied by over-production of IL-12, IFN-γ and TNF-α. J. Immunol. 157: 798-805.
81. Yu, M., J.M. Johnson, and V.K. Tuohy. 1996. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183:1777-1788.
82. McRae, B.L., C.L. Vanderlugt, M.C. Dal Canto, and S.D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182:75-85.
83. Tuohy, V.K., M. Yu, B. Weinstock-Gutman, and R.P. Kinkel. 1997. Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. 99: 1682-1690.